Mobocertinib
Mobocertinib is an oral tyrosine kinase inhibitor that specifically targets EGFR exon 20 insertion mutations in non-small cell lung cancer cells. It was designed for patients with locally advanced or metastatic NSCLC who have EGFR exon 20 insertions and have received prior platinum-based chemotherapy.
Mobocertinib is an EGFR inhibitor used to treat NSCLC with EGFR exon 20 insertion mutations, though it has been withdrawn from the market.
Key facts at a glance
- ATC
- L01EB10
- RxNorm
- 2570736
- Generic
- Mobocertinib
- Class
- atc-l01
- Brands
- Exkivity
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- capsule
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Mobocertinib was indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, following progression on or after platinum-based chemotherapy.
Mobocertinib is a small molecule tyrosine kinase inhibitor that irreversibly binds to and inhibits EGFR (Epidermal Growth Factor Receptor), particularly mutants containing exon 20 insertions, blocking downstream signaling pathways that promote cell proliferation and survival.
Mobocertinib was granted accelerated approval by the FDA in September 2021 but was subsequently withdrawn from the market in October 2022 due to safety concerns and commercial considerations. Common side effects included diarrhea, rash, nausea, vomiting, and decreased appetite. It required monitoring for QT prolongation and other serious adverse events.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy